CDMO, Samsung Biologics, has announced plans to construct a sixth manufacturing plant at its Bio Campus in Songdo, South Korea. Pending board approval, the expansion would increase the company's total production capacity to 964,000 liters by 2027. In addition, the company aims to establish a regional office in Tokyo, Japan by year-end to better serve its growing client base in one of the leading global markets.

Simultaneously, the company is investing in pre-filled syringe manufacturing, with a CGMP-compliant production line slated to be operational by 2027, alongside its recently launched ADC services to meet increasing demand.

The following article originally appeared in Fierce Pharma.

One day after Samsung Biologics revealed in a regulatory filing that it had signed its largest contract in company history, the CDMO giant said it's considering the construction of a sixth manufacturing plant.

The plan is a proactive response to the increased demand for biologics and would boost Samsung Biologics' total manufacturing capacity to 964,000 liters, pending board approval. The company’s fifth plant, which is set to become operational in April, will bring Samsung’s annual capacity to 784,000 liters.

The company provided the update in a press release concurrent with its presentation Tuesday at the J.P. Morgan Healthcare Conference in San Francisco.

Earlier this week, Samsung divulged in a public disclosure that it had signed a contract with an unidentified European client for 2.1 trillion South Korean won ($1.4 billion). The deal, which runs through the end of 2030, tops the company’s previous record contract of $1.2 billion, which Samsung signed three months ago with an unidentified Asian pharmaceutical company.

“Despite industry challenges, Samsung Biologics is well positioned to kick-start a new phase of growth in 2025 with the opening of Bio Campus II and launch of antibody-drug conjugate (ADC) services,” John Rim, Samsung Biologics CEO, said in the release.

In the Songdo area of Incheon, South Korea, Samsung has two adjacent sites. Bio Campus I includes four operational plants. The company envisions Bio Campus II also to eventually include four plants, each with a capacity of 180,000 liters.

In other company updates, Samsung said it plans to open a regional office in Tokyo by the end of this year. It is also investing to add pre-filled syringe manufacturing, with a line expected to be ready by 2027.

Last week, Samsung announced an extension of its partnership with South Korean ADC specialist LigaChem Biosciences.

For more, please find the original story source here.